Gliomatosis Peritonei and Its Relation to Teratoma: Role of Imaging and Histological Aspects

Tarang Patel 1, Virendrakumar Meena 2

1. Pathology, All India Institute of Medical Sciences (AIIMS), Rajkot, IND 2. Radiology, Geetanjali Medical College & Hospital, Udaipur, IND

Corresponding author: Tarang Patel, tarangpatel_86@yahoo.co.in

Abstract

Gliomatosis peritonei (GP) is a rare disease, usually associated with immature ovarian teratoma. GP may be rarely associated with mature ovarian teratoma. GP is composed of mature glial tissue elements, which histopathological examination can further confirm. Benign glial implants usually involve the omentum, peritoneum and lymph nodes. Many benign and malignant peritoneal diseases may mimic GP on clinical examination. GP may be confused with peritoneal carcinomatosis on computed tomography (CT) scan. A microscopic examination from peritoneal mass biopsy helps to rule out differential diagnosis. GP consists of mature glial tissue and is regarded as grade 0 according to the WHO grading of immature teratoma (IT). GP corresponds to a good prognosis with occasional cases showing malignant evolution.

Introduction And Background

Gliomatosis peritonei (GP) is identified by multiple nodules affecting the omentum and peritoneum, and it shows mature glial tissue on histological examination. GP may be associated with immature or mature ovarian teratoma [1-3]. Cases have been published regarding the association of GP with hepatic teratoma, gastric teratoma and even immature endometrial teratoma [4-6]. Two theories prevail regarding the aetiology of GP. According to the first theory, GP results from rupture of ovarian teratoma capsule or angio-lymphatic tumour spread [7]. However, the second concept suggests that foci of peritoneal glial tissue arise autonomously from Mullerian stem cells under favourable peritoneal conditions [8]. CT imaging is helpful for the diagnosis and follow-up of immature teratoma (IT) and peritoneal glial implants. Surgery is performed in GP associated with teratoma, whereas chemotherapy is recommended in the case of IT [9].

Review

Clinical and radiological features

IT clinically presents as a large pelvic mass, primarily turning up in the first three decades. Serum tumour markers like alpha-fetoprotein (AFP) are within normal limits [10]. On CT, IT shows some characteristic features. Mature teratoma (MT) are predominantly cystic tumours containing solid areas with large foci of fatty tissue that can be identified in radiology.

MT is usually well encapsulated with regular margins and foci of bony tissue within cystic elements. Compared to MT, IT is larger (14-25 cm) and shows predominantly solid components. IT usually presents with capsule perforation and irregular margins on a CT scan. Foci of punctate fatty tissue and scattered calcifications in a solid ovarian mass on CT scan discriminate IT from MT (Figure 1).
The combination of positron emission tomography (PET) and CT gives the additional benefit of providing morphologic and functional details in the case of IT [11].

GP on CT scan can present as multiple nodules involving the peritoneum and omentum with free fluid in the peritoneal cavity. The size of the peritoneal nodule varies from 0.3 to 1.2 cm in diameter [12]. It is challenging to differentiate peritoneal metastasis from GP on radio-imaging alone. Glial nodules are usually small in size without any adipose tissue component, making it impossible to separate tuberculous peritonitis or peritoneal carcinomatosis from glial nodules on imaging (Figures 2A-2B).

Radiology provides details concerning tumour staging and further surgery planning [13].

**Gross and morphology**

Intraoperatively GP may mimic peritoneal carcinomatosis. Grossly, GP presents multiple nodules having size ranging from 1 to 10 mm in diameter. They are small, greyish and well-circumscribed involving parietal and visceral peritoneum and omentum. Grossly it is challenging to differentiate GP from tuberculosis. IT presents as a large ovarian mass having an irregular outer surface. Tumour is mostly unilateral with cut surface showing mainly solid areas with focal cystic regions along with necrosis and haemorrhage [9,10].

Microscopically, IT is defined by immature tissue components, mainly immature neuroepithelium in the
form of rosettes and primitive neuroectodermal tissue in the background of mature teratomatous elements. Histology shows mitotically active primitive cells with dark hyperchromatic nuclei and glial tissue foci in the backdrop (Figures 3A-3D).

![Figure 3: Immature teratoma ovary (Source: own photo)](image)

A) Section shows primitive neuroepithelium (arrow) embedded in the fibrillary background (H&E; 4×). B) Immature component in the form of primitive neural tubes (star) (H&E; 20×). C) Section shows foci of the immature neuroepithelium (arrow) in the background of mature glial tissue (H&E; 20×). D) Low-power view showing mature components in the form of mature brain tissue (star) and mature bony tissue (arrow) (H&E; 10×).

IT may present with immature mesodermal tissue in the form of immature cartilage. Very rarely, IT may show immature endodermal tissue. The case of IT should not show components of a yolk sac tumour; otherwise, the case will be labelled as a mixed germ cell tumour. If a histological picture of IT and serum AFP levels are raised, further additional sampling must be carried out to rule out any component of the yolk sac tumour [9,10].

According to WHO classification of Female Genital Tumours, 5th Edition; grading is decided by examining immature neuroepithelium under a low-power microscopic view (40×). If the aggregated amount of neuroepithelium is present in one or less than one 40× field, it is grade 1; if present in one to three 40× fields, it is grade 2 and if present in more than three 40× fields, it is classified as grade 3 IT. Here, 40× power is equivalent to a 4.5 mm diameter view. Interestingly, pure GP is regarded as a grade 0 (zero) mature component. It shows multiple nodules of mature glial tissue beneath the surface [10] (Figures 4A-4D).
FIGURE 4: Gliomatosis peritonei histopathology (Source: own photo)

A) Ovarian surface multiple superficial nodules of mature glial tissue (star) (H&E; 10×). B) Metaplastic glial elements (star) with diffuse arrangement on ovarian surface in a case of immature teratoma grade 1. Underlying ovarian stroma is evident (arrow) (H&E; 10×). C) Omentum shows multiple glial nodules (star) with reactive inflammatory stroma (H&E; 10×). D) Peritoneum showing gliomatosis in the form of multiple tiny glial nodules (star) infiltrating fibrolipomatous stroma (H&E; 4×).

On immunohistochemistry, GP cells show characteristic positivity with SOX2 because SOX2 is necessary for preserving stem cell pluripotency and induction of neural cells origin from stem cells [14].

Genetic profile

Best et al. presented molecular studies in patients of ovarian mass diagnosed as IT with GP. Results showed that genetic changes in both lesions were mutually exclusive, indicating that neoplasms of IT and GP are genetically discrete. So, both are independent tumours, and GP does not represent tumour metastasis or tumour recurrence from IT mass [15]. Another study by Ferguson et al. showed heterozygosity at different microsatellite loci and homozygosity at the identical microsatellite loci of cases of the peritoneal glial nodule and ovarian IT mass, respectively. So, this leads to an impression that GP arises from pluripotent stem cells of Mullerian origin and is not related to primary ovarian teratoma [1].

Differential diagnosis

Growing teratoma syndrome (GTS) is a distinct entity characterised by a growing mass of MT in a known case of malignant germ cell tumour undergoing or having completed chemotherapy. GTS may contain mature tissue from any of three lineages, whilst GP shows only mature glial tissue. Unlike GTS, GP is not associated with chemotherapy treatment of malignant germ cell tumours [16].

In some cases of ovarian teratoma, predominantly MT components are seen. If clinically, radiologically and grossly suspicious of immature or malignant nature, then extensive sampling should be conducted to detect any immature neuroepithelium and also need for accurate grading of the immature component. Peritoneal carcinomatosis and tuberculous peritonitis can be easily differentiated from glial nodules on histology [9,10].

Prognosis and predictive factors

The patient is staged according to TNM staging of the ovary, fallopian tube and primary peritoneal carcinoma. Although GP is considered a stage III disease, its behaviour is mainly observed as benign [10].

GP is considered a grade 0 (zero), so it usually bears an overall favourable prognosis and is treated conservatively accordingly [13]. As GP lesion is mostly widespread, extensive surgical excision is indispensable. However, luckily, any residual lesion of GP is asymptomatic and requires no further action,
which may vanish over a long period of time [17]. Treatment is not decided based on metastatic glial tissue component but on the grade of primary ovarian IT, as long as the glial tissue has been extensively sampled and contains only mature tissue [18]. Although, if the peritoneal glial component is immature, it is considered a metastatic teratoma and treated accordingly [13]. At present, due to the rarity of this lesion, data are scarce regarding how long these cases should be pursued for follow-up.

Conclusions

GP is an uncommon disease usually associated with IT of the ovary. In the case of ovarian teratoma, radiologic imaging may help predict the immature or malignant nature of teratoma based on the identification of speckles of fatty tissue. In such suspected cases of IT, peritoneal and omental lesions should be searched, if any and should be excised along with ovarian mass to be sent for histopathological examination.

Grossly, throughout sampling should be carried out from ovarian mass to detect any immature neuroepithelium or other immature mesodermal components. A combined clinical, radiological and histopathological diagnostic approach is required to confirm the GP associated with IT and to differentiate it from its mimickers. It is also vital to acknowledge the benign mature nature of GP in most cases which helps to avert any avoidable surgical procedure in young patients.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Ferguson AW, Katabuchi H, Ronnett BM, Cho KR: Glial implants in gliomatosis peritonei arise from normal tissue, not from the associated teratoma. Am J Pathol. 2001, 159:51-5. 10.1016/S0002-9440(10)61672-0
2. Gocht A, Lohler J, Scheidel P, Stegner HE, Saeger W: Gliomatosis peritonei combined with mature ovarian teratoma: immunohistochemical observations. Path Res Pract. 1995, 191:1029-35. 10.1016/S0344-0358(11):86053-5
3. Calder CI, Light AM, Rollason TP: Immature ovarian teratoma with mature peritoneal metastatic deposits showing glial, epithelial, and endometrioid differentiation: a case report and review of the literature. Int J Gynecol Pathol. 1994, 13:279-82. 10.1097/00004347-199407000-00013
4. Karlo C, Leschka S, Dettmer M, Breitenstein S, Stolzmann P: Hepatic teratoma and peritoneal gliomatosis: a case report. Cases J 2009, 2:9502. 10.1186/1757-1626-2-9502
5. Coulson WF: Peritoneal gliomatosis from a gastric teratoma. Am J Clin Pathol. 1990, 94:87-9. 10.1095/ajcp/94.1.87
6. Anazah-Boateng Y, Wells M, Poole DR: Coexistent immature teratoma of the uterus and endometrial adenocarcinoma complicated by gliomatosis peritonei. Gynecol Oncol. 1985, 21:106-10. 10.1016/0090-8258(85)90240-9
7. Robboy SJ, Scully RE: Ovarian teratoma with glial implants on the peritoneum: an analysis of 12 cases. Hum Pathol. 1970, 1:643-53. 10.1016/0196-8177(70)90062-4
8. Dallenbach-Hellweg G: Critical commentary to "Gliomatosis peritonei combined with mature ovarian teratoma". Pathol Res Pract. 1995, 191:1037.
9. Marsnah N, Batra A, Gupta S, Singhal SR, Sen R: Gliomatosis peritonei arising in setting of immature teratoma of ovary: a case report and review of literature. J Obstet Gynaecol India. 2016, 66:192-5. 10.1095/ajcp/94.1.87
10. Vang R, Zaloudek C: Immature teratoma of the ovary. WHO classification of female genital tumours, 5th ed. Cheung AN, Ellenson LH, Gilks CB, et al. (ed): WHO Classification of Tumours Editorial Board, International Agency for Research on Cancer (IARC), Lyon; 2010. 70:121-2.
11. Wang M, Jiang S, Zhang Y, Jiang C, Luo W, Ma X: The application of 18F-FDG PET/CT in ovarian immature teratomas when pathological examination results contradict clinical observations: a case report. Medicine. 2017, 96:e9171. 10.1097/MD.0000000000009171
12. Lin CS, Huang C, Li PC, Hsu YH, Ding DC: Huge ovarian mature cystic teratoma with gliomatosis peritonei and massive ascites in a postmenopausal woman. Ci Yi Yi Xue Za Zhi. 2019, 31:289-91. 10.4103/tcmj.tcmj_176_18
13. Bajracharya A, Shrestha S, Singh M, Dhakal HP: Mature ovarian teratoma with gliomatosis peritonei: a rare case report. Clin Case Rep. 2021, 9:e04879. 10.1002/ccc.3.4879
14. Liang L, Zhang Y, Malpica A, Ramalingam P, Euscher ED, Fuller GN, Liu J: Gliomatosis peritonei: a clinicopathologic and immunohistochemical study of 21 cases. Mod Pathol. 2015, 28:1615-20. 10.1038/modpathol.2015.116
15. Best DH, Butz GM, Moller K, Coleman WB, Thomas DB: Molecular analysis of an immature ovarian teratoma with gliomatosis peritonei and recurrence suggests genetic independence of multiple tumours. Int J Gynaecol Obstet. 2004, 25:17-25. 10.3892/ijo.25.1.17
16. Mrobat H, El Ghissassi I, Shitti Y, Amrani M, Hachi H, Erihani H: Growing teratoma syndrome and
peritoneal gliomatosis. Case Rep Med. 2011, 2011:123527. 10.1155/2011/123527
17. Bentivegna E, Gonthier C, Uzan C, Genestie C, Durvillard P, Morice P, Gouy S: Gliomatosis peritonei: a particular entity with specific outcomes within the growing teratoma syndrome. Int J Gynecol Cancer. 2015, 25:244-9. 10.1097/IGC.0000000000000345
18. Srisaijakul S, Prapaisilp P, Bangchokdee S: Imaging features of unusual lesions and complications associated with ovarian mature cystic teratoma. Clin Imaging. 2019, 57:115-23. 10.1016/j.clinimag.2019.05.013